MRI waiting period eliminated for Taxus:
This article was originally published in Clinica
Boston Scientific has received for its drug-eluting stent (DES), Taxus, a new clearance from the US FDA that allows MRI to be performed on patients immediately following the device's implantation. Taxus is the first DES to be approved for immediate MRI exams, the firm claimed, adding that the approval also applied to the bare-metal version of the stent. Coronary stent recipients can now avoid the two-month waiting period previously required before undergoing MRI during the most critical stage of their recovery, said the firm. In a separate announcement, Boston said it has become the first company to offer a full range of DES sizes, with the launch of three large sizes of Taxus (for vessel sizes of between 4-5mm). The new sizes are set for immediate launch in Europe and in other countries outside the US.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.